Sponsor overview

Stichting European Myeloma Network

Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.

Back to report

Summary

Signal counts

Assets tracked: 1

Watchlist assets: 1

Registry stop assets: 1

Evidence links

Public sources

https://clinicaltrials.gov/study/NCT04617925 | https://clinicaltrials.gov/study/NCT07217184 | https://clinicaltrials.gov/study/NCT04126200 | https://clinicaltrials.gov/study/NCT07150091 | https://clinicaltrials.gov/study/NCT06655818 | https://clinicaltrials.gov/study/NCT07150104 | https://clinicaltrials.gov/study/NCT05064358

Assets

Linked programs

Belantamab mafodotin: Registry Stop Signal (5/5)